Thymosin Alpha-1 Non-Responder Profile: Who Doesn't Benefit and Why

What does 'non-responder' mean for this peptide?

Response only means something when it is measured against a defined endpoint in a defined group. The chronic hepatitis B trials measured endpoints such as HBeAg loss, HBV DNA clearance, ALT normalization and liver histology [6][1][5]. Someone who reports feeling nothing after a course of peptide has not been measured against any of them.

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymosin fraction 5; thymalfasin is the synthetic version with the same sequence, and Zadaxin is the finished 1.6 mg injection sold outside the United States [2]. It is described as an immune modulator that augments T-cell function, and after subcutaneous injection in healthy volunteers it peaks at about 0.7 to 2 hours and clears with a half-life of about 1.8 to 2.6 hours, with no accumulation over five daily doses [2][6].

What did the combination trial show?

In a double-blind, placebo-controlled trial, 98 adults with HBeAg-positive chronic hepatitis B received 24 weeks of lymphoblastoid interferon plus either thymosin alpha-1 (48 people) or placebo (50 people) [5]. Loss of HBeAg at 72 weeks was 45.8% with thymosin alpha-1 and 28.0% with interferon alone, a difference of 17.8% (95% CI -1.2 to 35.3) that was not statistically significant (P=0.067) [5]. More than half of the thymosin alpha-1 group did not reach that endpoint, and 72% of the interferon-alone group did not reach it either [5].

Why does the timing of the measurement change the answer?

A 2008 meta-analysis pooled four randomised trials with 199 patients comparing thymosin alpha-1 with interferon alpha [3]. At the end of six months of treatment the odds of a complete response were lower with thymosin alpha-1 (OR 0.54, 95% CI 0.30 to 0.97), and the virological and biochemical odds ratios pointed the same way without reaching significance [3]. Measured six months after treatment ended, the odds reversed: virological response OR 3.71 (95% CI 2.05 to 6.71), biochemical response OR 3.12 (1.74 to 5.62), complete response OR 2.69 (1.47 to 4.91) [3]. For three of the four trials the results applied mostly to HBeAg-negative chronic hepatitis B [3].

A 2004 review of seven randomised controlled trials of thymosin alpha-1 monotherapy at 1.6 mg twice weekly for six months reported a significantly higher sustained response than untreated controls, and noted that the benefit is usually not apparent during therapy, with a trend for complete virological response to accumulate gradually after treatment ended [8].

How often did untreated people clear the virus?

In one randomised controlled trial, HBV DNA cleared in 40.6% of patients treated for six months and 25.6% of those treated for twelve months, compared with 9.4% of untreated controls [6]. A 1991 pilot gave thymosin fraction 5 or thymosin alpha-1 to 7 people with chronic hepatitis B and placebo to 5, twice weekly for six months; serum HBV DNA cleared in 6 of 7 (86%) and in 1 of 5 (20%) on placebo (P<0.04) [9]. Twelve people is far too few to build a responder profile on, and one of the seven thymosin-treated patients in that pilot did not clear the virus [9].

What does the Cochrane review conclude?

A 2026 Cochrane review included 10 randomised trials with 1,349 adults, published between 1991 and 2018 and run in Bangladesh, China, Italy, Korea, Singapore and Taiwan [1]. Thymosin alpha-1 was given alone or with interferon, lamivudine, entecavir or tenofovir, and compared with placebo, no treatment or the same co-treatment [1]. All-cause mortality may have been lower with it (RR 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people), but the certainty was very low; there was little to no effect on quality of life or on liver histology, and the effect on hepatitis B-related illness was very uncertain [1]. The reviewers said they are 'not sure' thymosin alpha-1 helps [1]. The review looked only at trials in chronic hepatitis B.

Who does the label say should not take it?

The Italian label for Zadaxin — the finished 1.6 mg vial, not bulk powder — authorises it as an adjuvant to influenza vaccination in immunocompromised people, given subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, then repeated from week 8 to week 12 at the second vaccination [2]. That label says it is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [2]. Those are label cautions, not a prediction of who will fail to respond.

In India the approved use is chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication, and Zadaxin is also authorised in Hong Kong [2]. Two older reviews from authors tied to the developer say it is approved in over 35 countries (2009) or more than 30 countries (2007) [10][11]. In the United States it is not approved: FDA's December 2024 review notes four orphan drug designations, which is a separate process from approval [2]. The European Medicines Agency has granted only an orphan designation, for hepatocellular carcinoma [2].

Which product was used?

A report of no effect does not establish which product was used. Zadaxin and bulk thymosin alpha-1 powder are not interchangeable [2].

FDA's page on bulk substances that may raise significant safety risks lists thymosin alpha-1 in its nominated-but-withdrawn table, and its stated concerns remain: significant risk of immunogenicity for certain routes of administration, peptide-impurity and characterisation problems, and safety information that is inadequate for the agency to understand the extent of any safety issues [12]. On FDA's list for outsourcing facilities the peptide sits in category 3, 'nominated without adequate support' [13]. On 4 December 2024 FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety [4]. Thymosin alpha-1 is also not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [14].

What is known about harm?

In the 2026 Cochrane review, thymosin alpha-1 may have caused fewer serious adverse events than the comparison treatments (RR 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) and fewer non-serious adverse events (RR 0.47, 95% CI 0.27 to 0.83; very low-certainty evidence) [1]. FDA's search of its adverse-event database on 22 April 2024 found zero reports for the peptide [2]. Authors tied to the manufacturer report more than 4,400 people enrolled in trials and more than 17 million doses given after marketing, with adverse experiences 'infrequent and mild'; that is company-linked data [2]. The 1991 pilot reported no significant side effects in its 12 patients [9].

Bottom line

In the hepatitis B trials, response was measured with outcomes such as HBeAg loss at 72 weeks and HBV DNA clearance [6][5]. The timing of the measurement moved the answer: at the end of six months of treatment the odds of a complete response were lower with thymosin alpha-1 than with interferon, and six months after treatment ended they were higher [3]. A personal sense of feeling better, or of feeling nothing, is not one of those endpoints. Separately, FDA has posted concerns about immunogenicity, peptide impurities and inadequate safety information for compounded thymosin alpha-1 [12].